Speaker Profile
Ph.D., Director, Advance Genomics, Resilience
Biography
Neeraj Salathia has over 15 years of experience working in the biopharmaceutical industry and currently directs the Advanced Genomics RD team at Resilience. His work focusses on understanding the biological characteristics of complex medicines, such as cell- and gene- therapies, as they relate to biomanufacturing processes and ultimately clinical efficacy. Prior to joining Resilience, Neeraj led genomics-centric research efforts at Bristol Myers Squibb, supporting drug discovery research covering neurobiology, oncology and autoimmune disease indications. He has also worked at Celgene and Illumina developing novel assays for single cell biology and non-invasive cancer detection. Neeraj trained in molecular genetics and received his graduate degree from the University of Warwick, UK, followed by postdoctoral research at Harvard University and Novartis.
Talk
Rapid Multi-Omics Cell Therapy Characterization and QC
Resilience aims to translate advances in cell therapy research for patient benefit by developing a multi-omics assay platform for characterization of cell therapy products and consolidated QC release. This solution will significantly reduce manufacturing times and costs while enhancing understanding of drug product characteristics and associated patient clinical outcomes.
Emerging Therapeutics Showcase:
Resilience
Resilience is a technology-focused biomanufacturing company driving the pursuit of novel medicines across diverse disease modalities. We harness innovation to revolutionize how these therapeutics are made, funded and scaled.
Session Abstract – PMWC 2025 Silicon Valley
The PMWC 2025 Emerging Therapeutics Showcase will provide a 15-30 minute time slot for selected companies and researchers in the CRISPR, Cell and Gene Therapy fields. Major advancements in safer cell- and gene-level editing technologies are bringing us closer toward cures for life-threatening disorders, from cancer to HIV to Huntington’s disease. Cell therapy, in which cellular material such as T cells capable of fighting cancer cells, is injected into a patient, has been demonstrated safe and effective. The popular new CRISPR tool that has been used to edit the genetic code of nearly any organism will have an enormous impact on human health. More than a dozen clinical trials employing CRISPR on human cells are already underway.
- Emerging Therapeutics/Cell Therapy
- Emerging Therapeutics/CVD
- Emerging Therapeutics/Gene Therapy
- Emerging Therapeutics/Immunotherapy
- Emerging Therapeutics/Radiation Therapy
